Changes in Hong Kong stocks | Verishibo-B (09887) rose more than 10% in the afternoon, Velisin WCLC summary announced that the Three Antibodies received a global license of 10 million US dollars

The Zhitong Finance App learned that Weilizhibo-B (09887) rose more than 10% in the afternoon. As of press release, it had risen 9.16% to HK$76.9, with a turnover of HK$213 million.

According to the news, Weilizhibo announced that the full summary of the Phase II clinical study of PD-L1/4-1BB bispecific antibody Verisin® (LBL-024) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC), developed independently by the company, has been officially released on the official website of the World Lung Cancer Conference (WCLC). Based on data analysis as of March 6, 2026, Verisin® combined chemotherapy showed an encouraging objective remission rate (ORR) in the overall population, and strong tumor shrinkage effects were observed in both squamous cell carcinoma and non-squamous cell carcinoma subgroups. The data published in this summary was followed up for only 3.6 months. The latest data with a follow-up period of more than 7 months will be published during the oral report of the conference on September 14.

Notably, Weilizhibo announced that its subsidiary Leads US has received written notice from partner Oblenio Bio, a subsidiary of aditum Bio, to officially exercise the right of option to reserve the global development and commercialization license for the BCMA/CD19/CD3 tri-specific T-cell conjugator LBL-051 in accordance with the agreement signed in November 2024. Oblenio Bio will pay a one-time non-refundable fee of $10 million to Verishibo.